Ongoing Clinical Trials for Labour Pain
This article describes a clinical trial currently investigating pain relief options during childbirth. The trial examines how oxycodone, a pain-relieving medication, works during labor and its effects on both mothers and newborns. This research is being conducted in Finland and focuses on understanding how the medication moves through the body during labor.
Clinical trial locations
- Finland
Study of oxycodone safety and effectiveness for pain relief during labor and its effects on newborns
This trial is investigating how oxycodone can help manage pain during childbirth. The research examines both the effectiveness of this medication for mothers in labor and its potential effects on newborns.
Who can participate:
Women who are at least 18 years old and currently in labor may be eligible for this study. Participants must have received oxycodone for pain management during labor. You need to be able to understand the study information and provide written consent to participate. It is important that you are willing to allow the research team to collect blood samples from you and from the umbilical cord after birth. You must be mentally capable of making independent decisions about joining the study and able to communicate effectively with the research team.
Who cannot participate:
This study is not suitable for women under 18 or over 55 years of age. You cannot participate if you are carrying more than one baby (multiple pregnancy) or if you have known allergies to oxycodone or similar medications. Women with severe medical conditions, significant liver or kidney problems, or pre-eclampsia (high blood pressure during pregnancy) are not eligible. The study also excludes women who are planning a cesarean section, have a history of substance abuse, or are currently taking medications that could interact with oxycodone. If you have participated in another clinical trial within the past 30 days, you cannot join this study. Women who are unable to understand or follow study instructions, or who have known fetal abnormalities, are also excluded.
What the trial involves:
The main goal of this research is to understand how oxycodone moves through the body during labor and to measure its levels in both the mother’s blood and the umbilical cord at birth. During labor, you will receive Oxanest (oxycodone) as an injection under the skin for pain relief. The medication is given at a concentration of 10 mg/ml through subcutaneous injection. At the time of birth, researchers will collect a blood sample from you and another sample from the umbilical cord. These samples will be analyzed to measure the levels of oxycodone and compare the amount of medication in your blood with that in the umbilical cord blood. The information gathered will help create a mathematical model showing how the medication behaves in the bodies of women during labor. Your participation ends after the blood samples are collected. The total study period runs from July 2024 to July 2025, though your individual involvement lasts up to two days.
Investigational medication:
The medication being studied is oxycodone, a strong pain-relieving drug that belongs to the opioid family. It works by binding to specific receptors in the brain and nervous system to reduce pain sensation. Oxycodone can provide effective pain relief for women during labor, but it may pass through the placenta and reach the baby. This is why the study focuses on measuring medication levels in both the mother and the umbilical cord to understand its effects on both mother and newborn.
Summary
Currently, there is one clinical trial investigating pain relief options during childbirth. This research is taking place in Finland and focuses specifically on understanding how oxycodone, an opioid pain medication, works during labor. The trial aims to provide valuable information about both the safety and effectiveness of this medication for mothers while also examining its potential effects on newborns. The research involves careful monitoring of medication levels in both maternal and umbilical cord blood to create a better understanding of how the drug moves through the body during labor. This study represents an important effort to improve pain management options for women during childbirth while ensuring the safety of both mother and baby.
